Syntara Limited · ASX:SNT
Syntara — Non-Deal Roadshow (May 2025)
24 slides from Syntara's roadshow presentation, May 7, 2025
Slide 1: Non-deal Roadshow
For personal use only Non-deal Roadshow Gary Phillips, CEO May 2025
Slide 2: Forward looking statement
Forward looking statement For personal use only This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cau
Slide 3: Investment Highlights
Investment Highlights For personal use only Australian-founded clinical Clinical Backed by specialist Focus on first-in-class and Funded to mid-2026 with stage drug developer. stage drug developer. healthcare investors – best-in-class drugs backed near term data to drive 52% institutional. by in hou
Slide 4: Shareholders & cash
Shareholders & cash Financial Information (ASX: SNT) Share Price & Volume - YTD For personal use only Share price – 6 May 2025 $0.061 Price (AUD) 0.1 Market cap A$99.1m 0.09 0.08 0.07 Cash balance (31 Mar 2025) A$18.0m 0.06 0.05 0.04 Enterprise value A$81.1m 0.03 0.02 0.01 0 Volume Institutional Own
Slide 5: Syntara Board
Syntara Board Significant international pharmaceutical experience For personal use only Dr Kathleen Metters Dr Simon Green Gary Phillips Hashan De Silva Chair Non-Executive Director Chief Executive Officer Non-Executive Director • Former Senior Vice President • Experienced senior global pharma • 30+
Slide 6: Global leader in lysyl oxidase chemistry and biology
Syntara is the global leader in lysyl oxidase chemistry and biology Multi year research program leveraged with extensive scientific collaborations worldwide has delivered three drugs For personal use only now in phase 1c/2 studies Lysyl oxidases mediate the final stage in fibrosis SNT-5505 in Oncolo
Slide 7: Preclinical science and collaborations validated in high impact publications
Preclinical science and collaborations validated in high impact publications. For personal use only Myelofibrosis • Treatment with lysyl oxidase inhibitor significantly reduced reticulin fibrosis and megakaryocyte cell number in GATA-1low mice and JAK2V617F female mice Pancreatic Cancer • SNT-5505 a
Slide 8: Myelofibrosis
Myelofibrosis A rare type of bone marrow cancer that disrupts the body's normal production of blood cells For personal use only Key Facts Primary Myelofibrosis is Current standard SNT-5505 characterised by a build up of scar of care (SoC): - JAK inhibition In contrast to SoC tissue (fibrosis) in bon
Slide 9: The role of lysyl oxidases in myelofibrosis
The role of lysyl oxidases in myelofibrosis SNT-5505 designed to improve the bone marrow microenvironment • Lysyl oxidase gene family upregulated in the bone marrow (BM) of myelofibrosis patients1 For personal use only • Increased lysyl oxidase activity adversely impacts BM health in several ways1:
Slide 10: SNT-5505 Phase 2a trial part 1; Monotherapy in JAK inhibitor treatment failures
SNT-5505 Phase 2a trial part 1; Monotherapy in JAK inhibitor treatment failures Demonstrates improvements in fibrosis grade, excellent safety profile and promising signs of clinical activity For personal use only Study Design Endpoints Trial Outlooks • IND approved Q3 2020 • SNT-5505 has been well •
Slide 11: Phase 1/2a Study of PXS-5505 and Ruxolitinib in Myelofibrosis
For personal use only Multicenter, Open-Label Phase 1/2a Study of PXS-5505 and Ruxolitinib in Patients With Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis (NCT04676529) Oral Presentation #1001 presented on Monday 9th December at ASH 2024 Contributing Invest
Slide 12: Aims/Methods
Aims/Methods SNT-5505-MF-101 Add-on to RUX (study in progress)1 For personal use only • This add-on phase aims to further evaluate the safety and efficacy of SNT-5505 (200 mg BID) in patients with MF on stable background regimens of ruxolitinib (RUX) over a 52-week period STUDY POPULATION DESIGN END
Slide 13: Baseline characteristics
Baseline characteristics Heterogenous population with a high disease burden1 • Study is ongoing – data extracted 14 Characteristic N=16 For personal use only Age, median (range), years 71 (46-82) Nov 2024 Sex, male, n (%) 7 (44) • 13 patients (pts) reached 12 week visit Time since MF diagnosis, medi
Slide 14: Safety
Safety SNT-5505 has been well tolerated with no treatment related SAEs1 For personal use only • Majority of AEs were mild, 44/61 Pts with Grade 3/4 AEs Regardless of Causality# (72%) ≤ Grade 2 Grade 3 Grade 4 • 82% of AEs considered not related Adverse Event N=16 N=16 to treatment Anemia 4 • 11 poss
Slide 15: Total symptom score
Total symptom score Improvements seen in TSS from Baseline to Week 121 For personal use only 100 • 6/13 pts (46%) achieved TSS50 10 • Median absolute change 50 TSS Change from Baseline (%) was -10 11 • Median % change was -41% Baseline TSS 37 52 51 45 22 16 18 32 19 23 10 0 -50 TSS50 -100 TSS50 is w
Slide 16: Total symptom score over time
Total symptom score over time Substantial reduction in TSS observed in the majority of patients1 100 For personal use only Week 12 • 8/13 pts (62%) reached TSS50 up Week 24 to Week 38 Week 38 • Improvement in TSS continue 50 TSS Change from Baseline (%) over time 11 • TSS improvement despite a prior
Slide 17: Spleen volume over time
Spleen volume over time Additional reductions seen with longer treatment1 50 45 Week 12 For personal use only 40 Week 24 • 11/13 pts had spleen volumes at 35 * Week 38 baseline > 450 cm3 30 * 25 Spleen Volume Change % • 9/11 pts (82%) had either stable or 20 15 reduced spleen volume 10 1353 Baseline
Slide 18: Efficacy outcomes at Week
Efficacy outcomes at Week 38 Longer duration of therapy leads to additional improvements1 For personal use only Baseline TSS Baseline Spleen Volume (cm3) 10 52 22 45 18 23 0 5 602 478 3832 3050 2153 Pt # 1 Pt # 2 Pt # 3 Pt # 4 Pt # 5 0 Pt # 4 Pt # 2 Pt # 5 Pt # 1 Pt # 3 Spleen Volume Change (%) -5 -
Slide 19: Competitive landscape
Competitive landscape Data from comparative open label phase 2 studies for drugs currently under late stage development in MF Drug Latest Program Phase 2 Open Label Trial results in suboptimal patient population Status N Baseline characteristics Safety TSS50 SVR35 (median, range) Grade 3/4 events ≥
Slide 20: Strong interest in myelofibrosis assets from strategics
Strong interest in myelofibrosis assets from strategics Target / Acquiror / / For personal use only Date of Feb-2024 June-2023 July-2022 Announcement Drug Name Pelabresib Pacritinib Momelotinib Lead Indication / Myelofibrosis Myelofibrosis Myelofibrosis Phase (Successful Phase 3 (Marketed) (FDA File
Slide 21: Conclusions
Conclusions Interim data1 suggests SNT-5505 combined with ruxolitinib may deliver deep and long lasting benefit to patients who are sub-optimally controlled on ruxolitinib alone For personal use only Consistent with Despite the relatively Reductions in Additional data from monotherapy data2, small s
Slide 22: Targeting multiple near term opportunities in high value markets
Targeting multiple near term opportunities in high value markets For personal use only Anticipated Upcoming Addressable market Drug Candidate Indication Phase Milestones (US$) Interim 12 month data Myelofibrosis Phase 2 ~$1 billion1 June 2025 SNT-5505 Myelodysplastic Syndrome Low & intermediate Risk
Slide 23: Recent & anticipated news flow
Recent & anticipated news flow Strong and growing pipeline with advancement in studies expected to provide value inflection points Key Event For personal use only • Latest phase 2a COMPLETED Q1 2025 June 2025 Q2 2025 Mid 2025 9/12 month Q4 2024 myelofibrosis data SNT-5505 Phase 2a Syntara skin SNT-5
Slide 24: Gary Phillips, Chief Executive Officer
For personal use only Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au www.syntaraTX.com.au LinkedIn Twitter Logo WhiteOnBlue